AstraZeneca to supply Europe with up to 400 million doses of COVID-19 vaccine
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
List view / Grid view
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
A report suggests that India’s CMO market has recently attracted investment from global private equity firms due to favourable government policies.
This whitepaper studies the effect of humidity on tablet surfaces containing different types of super disintegrants.
Superdisintegrants are categorised by their mechanism of action such as wicking, swelling or shape recovery. In this study, the performance of disintegrants from each of these groups was tested in an insoluble, hydrophobic tablet formulation.
Watch how PROSOLV® EASYtab, the all-in-one excipient composite, offers superior disintegration for your tablet formulations.
Discover JRS PHARMA's industry leading manufacturing network for Microcrystalline Cellulose.
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
A new report has outlined that AstraZeneca has been granted protection from product liability claims regarding its COVID-19 vaccine candidate.
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
President Donald Trump has signed the 'Buy American' executive order, which is meant to reduce drug prices and protect the US from supply chain disruptions.
Robust and sensitive, the PyroMAT® Monocyte Activation Test system is a non-animal based method for the detection of endotoxin and non-endotoxin pyrogens. Download our studies
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
4 August 2020 | By Thermo Fisher Scientific
Find out more about industry issues, solutions, trends and how LIMS can enable laboratories to accelerate science and drive productivity, while ensuring regulatory compliance in our on-demand webinar.
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.